PDCD2L过表达是一个不利的预后标志物,抑制其在胃癌中显示出良好的治疗潜力。

IF 1.9
Ding-Ping Sun, Chun-Chao Chang, Hsuan-Yi Huang, Nai-Weng Kang, You-Cheng Hseu, Yu-Feng Tian, Chia-Lang Fang, Kai-Yuan Lin
{"title":"PDCD2L过表达是一个不利的预后标志物,抑制其在胃癌中显示出良好的治疗潜力。","authors":"Ding-Ping Sun, Chun-Chao Chang, Hsuan-Yi Huang, Nai-Weng Kang, You-Cheng Hseu, Yu-Feng Tian, Chia-Lang Fang, Kai-Yuan Lin","doi":"10.1177/18758592251374857","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundGastric cancer is the 4th most common and 3rd deadliest cancer worldwide. Research has shown that PDCD2-like (PDCD2L) is elevated in several tumors.ObjectiveTo explore the relationship between PDCD2L expression and gastric cancer prognosis and its function in gastric cancer.MethodsImmunohistochemical staining and immunoblotting were performed to examine the expression of PDCD2L. The effect of PDCD2L on gastric cancer cells were evaluated by a series of in vitro cellular function experiments and in vivo proliferation experiments.ResultsPDCD2L was found to be overexpressed in gastric cancer tissues compared to non-tumor tissues, and its higher levels were associated with worse prognosis. In vitro experiments showed that reducing PDCD2L expression in gastric cancer cells led to decreased proliferation, migration, and invasion, with a similar effect observed in animal models. Knockdown of PDCD2L also resulted in lower expression of cell cycle- and motility-related proteins, while upregulation of PDCD2L had the opposite effect. Additionally, NGS analysis revealed that PDCD2L knockdown reduced the expression of RFX1, a gene linked to cell proliferation and migration, suggesting that PDCD2L and RFX1 together promote cancer progression.ConclusionPDCD2L could serve as a biomarker for gastric cancer prognosis and a potential therapeutic target.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 9","pages":"18758592251374857"},"PeriodicalIF":1.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PDCD2L overexpression represents an unfavorable prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer.\",\"authors\":\"Ding-Ping Sun, Chun-Chao Chang, Hsuan-Yi Huang, Nai-Weng Kang, You-Cheng Hseu, Yu-Feng Tian, Chia-Lang Fang, Kai-Yuan Lin\",\"doi\":\"10.1177/18758592251374857\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BackgroundGastric cancer is the 4th most common and 3rd deadliest cancer worldwide. Research has shown that PDCD2-like (PDCD2L) is elevated in several tumors.ObjectiveTo explore the relationship between PDCD2L expression and gastric cancer prognosis and its function in gastric cancer.MethodsImmunohistochemical staining and immunoblotting were performed to examine the expression of PDCD2L. The effect of PDCD2L on gastric cancer cells were evaluated by a series of in vitro cellular function experiments and in vivo proliferation experiments.ResultsPDCD2L was found to be overexpressed in gastric cancer tissues compared to non-tumor tissues, and its higher levels were associated with worse prognosis. In vitro experiments showed that reducing PDCD2L expression in gastric cancer cells led to decreased proliferation, migration, and invasion, with a similar effect observed in animal models. Knockdown of PDCD2L also resulted in lower expression of cell cycle- and motility-related proteins, while upregulation of PDCD2L had the opposite effect. Additionally, NGS analysis revealed that PDCD2L knockdown reduced the expression of RFX1, a gene linked to cell proliferation and migration, suggesting that PDCD2L and RFX1 together promote cancer progression.ConclusionPDCD2L could serve as a biomarker for gastric cancer prognosis and a potential therapeutic target.</p>\",\"PeriodicalId\":520578,\"journal\":{\"name\":\"Cancer biomarkers : section A of Disease markers\",\"volume\":\"42 9\",\"pages\":\"18758592251374857\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer biomarkers : section A of Disease markers\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/18758592251374857\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer biomarkers : section A of Disease markers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/18758592251374857","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

胃癌是世界上第四大最常见和第三大最致命的癌症。研究表明,pdcd2样蛋白(PDCD2L)在几种肿瘤中升高。目的探讨PDCD2L表达与胃癌预后的关系及其在胃癌中的作用。方法采用免疫组化染色和免疫印迹法检测PDCD2L的表达。通过一系列体外细胞功能实验和体内增殖实验,评价PDCD2L对胃癌细胞的影响。结果与非肿瘤组织相比,spdcd2l在胃癌组织中高表达,其表达水平越高,预后越差。体外实验表明,降低PDCD2L在胃癌细胞中的表达,可以减少癌细胞的增殖、迁移和侵袭,动物模型中也有类似的效果。PDCD2L的下调也会导致细胞周期和运动相关蛋白的表达降低,而PDCD2L的上调则会产生相反的效果。此外,NGS分析显示,PDCD2L敲低可降低与细胞增殖和迁移相关的RFX1基因的表达,表明PDCD2L和RFX1共同促进癌症进展。结论pdcd2l可作为胃癌预后的生物标志物和潜在的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
PDCD2L overexpression represents an unfavorable prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer.

BackgroundGastric cancer is the 4th most common and 3rd deadliest cancer worldwide. Research has shown that PDCD2-like (PDCD2L) is elevated in several tumors.ObjectiveTo explore the relationship between PDCD2L expression and gastric cancer prognosis and its function in gastric cancer.MethodsImmunohistochemical staining and immunoblotting were performed to examine the expression of PDCD2L. The effect of PDCD2L on gastric cancer cells were evaluated by a series of in vitro cellular function experiments and in vivo proliferation experiments.ResultsPDCD2L was found to be overexpressed in gastric cancer tissues compared to non-tumor tissues, and its higher levels were associated with worse prognosis. In vitro experiments showed that reducing PDCD2L expression in gastric cancer cells led to decreased proliferation, migration, and invasion, with a similar effect observed in animal models. Knockdown of PDCD2L also resulted in lower expression of cell cycle- and motility-related proteins, while upregulation of PDCD2L had the opposite effect. Additionally, NGS analysis revealed that PDCD2L knockdown reduced the expression of RFX1, a gene linked to cell proliferation and migration, suggesting that PDCD2L and RFX1 together promote cancer progression.ConclusionPDCD2L could serve as a biomarker for gastric cancer prognosis and a potential therapeutic target.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信